Evicenter
MarkdownMedical informationP&T meetings
Claseprubart (DNTH103)

Chronic inflammatory demyelinating polyneuropathy

Launch
Not announced
Last updated
143 sources

Product information and disease descriptionProduct descriptionProduct information

Co-prescribed/Concomitant therapies

5 evidence topics · 4 sources

Treatment at study entry: interim analysis of the first 40 participants
Prior treatment groupClaseprubart 300 mg every 2 weeks (N=40), n (%)
Standard of care treated“27 (67.5)”
Immunoglobulin“19 (47.5)”
Oral corticosteroids“8 (20.0)”
Standard of care refractory“9 (22.5)”
Treatment naive“4 (10.0)”